One-third of 33 recent US combat casualties evacuated from the Middle East were carrying bacteria resistant to multiple antibiotics, according to the Joint Staff’s top medical officer. Speaking at a military medical symposium in Florida, Maj. Gen. Clinton Murray, the Joint Staff surgeon and an infectious disease physician, reported that only one of those troops developed an active infection, while the others were colonized—meaning the bacteria were present but not causing illness.
The findings, while not indicative of an outbreak, signal a growing concern for military medical systems preparing for large-scale conflicts. Murray emphasized that the threat of antimicrobial-resistant organisms is likely to worsen without significant medical advances, describing it as a challenge that “is not going to go away” and “is only going to get worse.”
Battlefield Conditions Heighten Risks
Military experts warn that prolonged evacuation times and crowded medical facilities in high-intensity warfare could exacerbate infection risks. In such scenarios, severely wounded troops may wait days or weeks for evacuation, with wounds exposed to soil, debris, and bacteria. Surviving soldiers often pass through crowded hospitals, where pathogens can spread rapidly. The Ukrainian medical system has already faced similar challenges amid ongoing warfare, with resistant infections complicating recoveries.
Global Context and Military Preparedness
Murray noted that the observed colonization rates among US troops are consistent with global trends, including those seen in intensive care units worldwide. While colonization does not always lead to active infection, it underscores the persistent and evolving nature of antimicrobial resistance. Military leaders argue that this threat, though less visible than traditional weapons, could wreak havoc in future large-scale conflicts where high-end missiles and drones dominate discussions of battlefield challenges.
The military’s medical community is calling for improved infection detection and management on battlefields, highlighting the need for rapid diagnostics, targeted treatments, and infection control protocols to mitigate risks. As warfare evolves, so too must medical strategies to address the silent but escalating danger of drug-resistant bacteria.